NASDAQ:IMMU
Delisted
Immunomedics Stock News
$87.86
+0 (+0%)
At Close: May 27, 2022
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer | MarketScreener
02:31pm, Saturday, 19'th Sep 2020Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
02:30pm, Saturday, 19'th Sep 2020
Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard
Immunomedics : Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers | MarketScreener
12:01pm, Friday, 18'th Sep 2020Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers | MarketScreener
12:01pm, Friday, 18'th Sep 2020Advanced Dermatology and Cosmetic Surgery Announces the Appointment of Brian T. Griffin as Chief Executive Officer
12:00am, Wednesday, 16'th Sep 2020
Advanced Dermatology and Cosmetic Surgery (ADCS), a national leader in dermatology care, today announced that Brian T. Griffin has been appointed as C
Merger Monday Confirms An Active Stock Market - Buy Under-Appreciated Biotech
05:15pm, Tuesday, 15'th Sep 2020
I was very pleasantly surprised by the $70 billion worth of M&A announced yesterday. It confirmed that the stock market is alive and well.
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles
05:08pm, Tuesday, 15'th Sep 2020
The market is crazy high by most measures. Gilead's intention to buy Immunomedics for $21 billion shows the upside of monoclonal antibodies.
Gilead Is Buying Immunomedic. What the Bond Market Has to Say About the Deal.
04:09pm, Tuesday, 15'th Sep 2020
S&P Ratings put the company on watch for a downgrade—most likely to BBB+ from A—less than one day after the deal was announced.
Merger Arbitrage Mondays - Gilead Sciences Acquires Immunomedics At A High Premium
11:22pm, Monday, 14'th Sep 2020
Merger activity decreased last week, with two new deals announced. The acquisition of Immunomedics by Gilead Sciences.
A string of corporate mergers help provide insight into this market, Jim Cramer says
10:43pm, Monday, 14'th Sep 2020
CNBC's Jim Cramer advises investors not to be "too negative" the next time the market sells off, given the string of corporate acquisitions announced on Monday.
What Gilead's $21 Billion Oncology Bet Means For Investors
04:47pm, Monday, 14'th Sep 2020
Gilead makes a major oncology play, spending $21 billion on Immunomedics. When will the deal be accretive, and what does this mean? Gilead seems like a reasonable investment at the current price..
Gilead Bets Heavily in a Cancer Biotech Acquisition
02:00pm, Monday, 14'th Sep 2020
Gilead is paying $21 billion for Immunomedics and its promising new cancer treatment. Wall Street’s unsure Gilead will earn back the steep acquisition price.
Stocks jump at the open on vaccine, merger news
01:35pm, Monday, 14'th Sep 2020
U.S. stocks opened higher Monday, buoyed by deal-making and prospects for a COVID-19 vaccine. The Dow Jones Industrial Average undefined rose 192 points,...
Gilead Sciences And Immunomedics: Buy Post-Market Reaction
01:23pm, Monday, 14'th Sep 2020
Gilead Sciences has announced it's buying Immunomedics for $21 billion - we don't expect the market to react favorably.
